National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

< Back to Main
Page Options
Print This Page
E-Mail This Document
Browse by Cancer Type
Breast Cancer

Lung Cancer

Prostate Cancer

More Results
Search Trial Results

      
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Denosumab May Help Prevent Bone Loss

Past Highlights
Related Pages
Search for Clinical Trials
NCI's PDQ® registry of cancer clinical trials.

Soft Tissue Sarcoma Home Page
NCI's gateway for information about soft tissue sarcomas.
Soft Tissue Sarcoma Trial Results

6.  Imatinib Mesylate (Gleevec™) Shows Promise for Type of Gastrointestinal Tumor
(Posted: 07/20/2001, Reviewed: 12/20/2005) - Imatinib mesylate (Gleevec™), a new cancer drug approved on May 10, 2001, for the treatment of some types of leukemia, now appears also to work in a rare type of cancer called gastrointestinal stromal tumor (GIST). Two reports presented from early clinical trials of the drug, also called STI571, were presented at the 2001 annual meeting of the American Society of Clinical Oncology in San Francisco on May 14.
< Previous  1 2 


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov